Related Experiment Video
Updated: May 10, 2026
04:34
Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
Treatment-resistant insomnia treated with pregabalin
G Di Iorio1, I Matarazzo, L Di Tizio
1Department of Neuroscience and Imaging, University, G. d'Annunzio, Chieti, Italy.
European Review for Medical and Pharmacological Sciences
|June 18, 2013
Summary
This study highlights pregabalin as a potential treatment for refractory insomnia, particularly when linked to subsyndromal Restless Legs Syndrome (RLS). Pregabalin demonstrated significant efficacy where other treatments failed, offering a novel therapeutic avenue.
Area of Science:
- Neurology
- Psychiatry
- Pharmacology
Background:
- Insomnia is a common sleep disorder often co-occurring with psychiatric conditions like depression and anxiety.
- Refractory insomnia presents a significant clinical challenge, resisting conventional treatments.
Observation:
- A patient with depression, anxiety, and a sensory-motor disorder experienced persistent insomnia.
- Subsyndromal Restless Legs Syndrome (RLS) symptoms were present but did not meet full diagnostic criteria.
Findings:
- Standard treatments including antidepressants, antipsychotics, and benzodiazepines showed limited efficacy.
- Pregabalin was highly effective in treating the intractable insomnia with no reported side effects.
Implications:
- Pregabalin may be a valuable therapeutic option for resistant insomnia, especially in cases with subsyndromal RLS.
- This finding suggests a potential role for pregabalin in managing complex sleep-wake disturbances beyond established indications.
Related Concept Videos
01:19Management of Insomnia
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:27Insomnia
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
01:14CNS Depressants: Barbiturates and Benzodiazepines
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:23Sedatives and Hypnotics: Overview
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...